Annual Cash & Cash Equivalents
$92.15 M
-$564.05 M-85.96%
December 31, 2023
Summary
- As of February 20, 2025, IRWD annual cash & cash equivalents is $92.15 million, with the most recent change of -$564.05 million (-85.96%) on December 31, 2023.
- During the last 3 years, IRWD annual cash & cash equivalents has fallen by -$270.41 million (-74.58%).
- IRWD annual cash & cash equivalents is now -85.96% below its all-time high of $656.20 million, reached on December 31, 2022.
Performance
IRWD Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$88.21 M
-$17.31 M-16.41%
September 30, 2024
Summary
- As of February 20, 2025, IRWD quarterly cash and cash equivalents is $88.21 million, with the most recent change of -$17.31 million (-16.41%) on September 30, 2024.
- Over the past year, IRWD quarterly cash and cash equivalents has stayed the same.
- IRWD quarterly cash and cash equivalents is now -88.09% below its all-time high of $740.34 million, reached on March 31, 2023.
Performance
IRWD Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
IRWD Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -86.0% | 0.0% |
| 3 y3 years | -74.6% | -85.8% |
| 5 y5 years | -46.8% | -85.8% |
IRWD Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -86.0% | at low | -88.1% | at low |
| 5 y | 5-year | -86.0% | at low | -88.1% | at low |
| alltime | all time | -86.0% | +107.9% | -88.1% | +149.3% |
Ironwood Pharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $88.21 M(-16.4%) |
| Jun 2024 | - | $105.52 M(-13.2%) |
| Mar 2024 | - | $121.54 M(+31.9%) |
| Dec 2023 | $92.15 M(-86.0%) | $92.15 M(-16.3%) |
| Sep 2023 | - | $110.16 M(-37.2%) |
| Jun 2023 | - | $175.32 M(-76.3%) |
| Mar 2023 | - | $740.34 M(+12.8%) |
| Dec 2022 | $656.20 M(+5.8%) | $656.20 M(+14.3%) |
| Sep 2022 | - | $574.19 M(+13.8%) |
| Jun 2022 | - | $504.37 M(-15.0%) |
| Mar 2022 | - | $593.37 M(-4.3%) |
| Dec 2021 | $620.13 M(+71.0%) | $620.13 M(+8.0%) |
| Sep 2021 | - | $574.28 M(+16.6%) |
| Jun 2021 | - | $492.70 M(+12.4%) |
| Mar 2021 | - | $438.47 M(+20.9%) |
| Dec 2020 | $362.56 M(+104.8%) | $362.56 M(+17.9%) |
| Sep 2020 | - | $307.56 M(+21.4%) |
| Jun 2020 | - | $253.25 M(+9.6%) |
| Mar 2020 | - | $231.14 M(+30.6%) |
| Dec 2019 | $177.02 M(+2.2%) | $177.02 M(+27.1%) |
| Sep 2019 | - | $139.23 M(+40.8%) |
| Jun 2019 | - | $98.91 M(-16.9%) |
| Mar 2019 | - | $119.05 M(-31.3%) |
| Dec 2018 | $173.17 M(+37.7%) | $173.17 M(+22.3%) |
| Sep 2018 | - | $141.56 M(-2.6%) |
| Jun 2018 | - | $145.41 M(+0.4%) |
| Mar 2018 | - | $144.79 M(+15.2%) |
| Dec 2017 | $125.74 M(+132.8%) | $125.74 M(-22.7%) |
| Sep 2017 | - | $162.64 M(-10.7%) |
| Jun 2017 | - | $182.13 M(+36.6%) |
| Mar 2017 | - | $133.32 M(+146.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2016 | $54.00 M(-79.3%) | $54.00 M(-70.5%) |
| Sep 2016 | - | $182.94 M(-34.0%) |
| Jun 2016 | - | $277.33 M(-1.3%) |
| Mar 2016 | - | $280.93 M(+7.5%) |
| Dec 2015 | $261.29 M(+251.7%) | $261.29 M(+5.3%) |
| Sep 2015 | - | $248.08 M(-3.3%) |
| Jun 2015 | - | $256.45 M(+302.6%) |
| Mar 2015 | - | $63.69 M(-14.3%) |
| Dec 2014 | $74.30 M(-1.6%) | $74.30 M(+44.9%) |
| Sep 2014 | - | $51.27 M(-46.2%) |
| Jun 2014 | - | $95.36 M(-53.5%) |
| Mar 2014 | - | $205.13 M(+171.7%) |
| Dec 2013 | $75.49 M(-44.8%) | $75.49 M(-47.7%) |
| Sep 2013 | - | $144.45 M(-34.2%) |
| Jun 2013 | - | $219.46 M(+108.4%) |
| Mar 2013 | - | $105.30 M(-23.0%) |
| Dec 2012 | $136.70 M(+56.6%) | $136.70 M(+8.6%) |
| Sep 2012 | - | $125.87 M(+44.5%) |
| Jun 2012 | - | $87.08 M(-33.8%) |
| Mar 2012 | - | $131.61 M(+50.8%) |
| Dec 2011 | $87.28 M(+96.9%) | $87.28 M(+26.8%) |
| Sep 2011 | - | $68.82 M(+42.8%) |
| Jun 2011 | - | $48.19 M(+4.3%) |
| Mar 2011 | - | $46.21 M(+4.3%) |
| Dec 2010 | $44.32 M(-63.8%) | $44.32 M(+25.3%) |
| Jun 2010 | - | $35.38 M(-53.6%) |
| Mar 2010 | - | $76.34 M(-37.6%) |
| Dec 2009 | $122.31 M(+80.6%) | $122.31 M(+27.0%) |
| Sep 2009 | - | $96.27 M(+42.2%) |
| Dec 2008 | $67.72 M(+8.5%) | $67.72 M |
| Dec 2007 | $62.43 M | - |
FAQ
- What is Ironwood Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Ironwood Pharmaceuticals?
- What is Ironwood Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is Ironwood Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Ironwood Pharmaceuticals?
- What is Ironwood Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is Ironwood Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of IRWD is $92.15 M
What is the all time high annual cash & cash equivalents for Ironwood Pharmaceuticals?
Ironwood Pharmaceuticals all-time high annual cash & cash equivalents is $656.20 M
What is Ironwood Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, IRWD annual cash & cash equivalents has changed by -$564.05 M (-85.96%)
What is Ironwood Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of IRWD is $88.21 M
What is the all time high quarterly cash and cash equivalents for Ironwood Pharmaceuticals?
Ironwood Pharmaceuticals all-time high quarterly cash and cash equivalents is $740.34 M
What is Ironwood Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, IRWD quarterly cash and cash equivalents has changed by $0.00 (0.00%)